Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07415083 · ClinicalTrials.gov registry record
A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 13
- Enrollment target
NCT07415083 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 13 participants.
The verdict
NCT07415083 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The aim of this study was to investigate the safety, tolerability, and effectiveness of eltrombopag in combination with immunosuppressive therapy (IST) in real world practice in pediatric patients with severe aplastic anemia (sAA) in Korea. The study used data over a 6-month period extracted from patients' medical charts (electronic medical records) starting from the initiation of eltrombopag treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2025-02-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07415083
The ClinicalTrials.gov registry entry for NCT07415083 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07415083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07415083 about?
NCT07415083 is a clinical study titled "A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia". The aim of this study was to investigate the safety, tolerability, and effectiveness of eltrombopag in combination with immunosuppressive therapy (IST) in real world practice in pediatric patients with severe aplastic anemia (sAA) in Korea. The study used data over a 6-month period extracted from pa...
What is the current status of trial NCT07415083?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2023-06-21. Estimated completion is 2025-02-25.
Who is sponsoring clinical trial NCT07415083?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.